Effects of extracts from *Cordyceps sinensis* on M1 muscarinic acetylcholine receptor *in vitro* and *in vivo*

Tomohiro Chiba¹
Marina Yamada¹
Kosuke Torii²
Masataka Suzuki¹
Jumpei Sasabe¹
Minoru Ito²
Sadakazu Aiso¹

¹Department of Anatomy, Keio University, School of Medicine, Tokyo, Japan; ²Department of Research and Development, Noevir Co. Ltd., Tokyo, Japan

**Abstract:** Cholinergic dysfunction is implicated in the pathogenesis of memory impairment related to Alzheimer’s disease (AD). Accordingly, regulation of M1 muscarinic acetylcholine receptor (M1 mAChR) has been one of the major targets in the development of novel drugs for AD. Utilizing an *in vitro* system for evaluation of the M1 mAChR, we have recently identified that extracts from *Cordyceps sinensis* (CS) promote M1 mAChR function. In this study, we examined the effect of pretreatment with several types of CS extracts in F11 neurohybrid cells on ERK phosphorylation induced by a muscarinic agonist, carbachol (CCh). A mixed extract of a hot water extract and an ethanol extract from CS augmented ERK phosphorylation by CCh presumably through upregulation of M1 mAChR function. We further examined the effect of oral administration of CS extracts on memory impairment induced by a muscarinic antagonist scopolamine in mice, finding that CS extracts ameliorated scopolamine-induced amnesia *in vivo*, consistent with the *in vitro* data. Thus CS extracts may contribute to the prevention of memory impairment related to AD.

**Keywords:** *Cordyceps sinensis*, Alzheimer’s disease, m1-muscarinic acetylcholine receptor, memory impairment

Cholinergic dysfunction has been implicated in the pathogenesis of Alzheimer’s disease (AD). Progressive cholinergic denervation in the cerebral cortex as well as decreased levels of acetylcholine (ACh) and choline acetyltransferase (ChAT) has been reported to be associated with AD-relevant cognitive impairment.¹,² Similarly, acetylcholinesterase (AChE) inhibitors such as Donepezil, which increase ACh concentrations around the synaptic cleft by inhibiting ACh degradation, moderately improve cognitive function in AD patients.³–⁶ Given that augmentation of cholinergic neurotransmission contributes to alleviation of memory impairment related to AD, stimulation or activation of ACh receptors (AChRs) are also deemed to be promising targets for the development of a novel AD therapy.

There are two types of AChRs: muscarinic and nicotinic AChRs. The former muscarinic AChRs (mAChRs) are G protein-coupled receptors activating intracellular second messengers and the latter nicotinic AChRs are ligand-gated ion channels.⁷–⁹ Among the mAChRs, M1 mAChR (M1 mAChR) is likely to be that involved in AD pathogenesis for several reasons.¹⁰ (i) A specific M1 mAChR agonist improved hippocampal plasticity by potentiating N-methyl-D-aspartate receptor activity,¹¹ (ii) M1 mAChR-deficient mice showed severe memory impairment,¹² and (iii) M1 mAChR agonists attenuated memory impairment in an AD model.¹³ In our previous study, we found that the Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathway.
axis in hippocampal neurons is inactivated by Alzheimer’s amyloid-β (Aβ) peptide, which results in desensitization of M1 mAChR.\textsuperscript{14,15} We also reported that a novel neuroprotective peptide named colivelin promoted M1 mAChR function by activating the JAK2/STAT3 axis in hippocampal neurons and ameliorated memory impairment in multiple AD models \textit{in vivo}.\textsuperscript{14,15}

Phosphorylation of extracellular-signal regulated kinase (ERK) through M1 mAChR is reported to play important roles not only in the induction of long-term depression in the rat hippocampus,\textsuperscript{16} but also in the neuronal differentiation in hippocampal pyramidal neurons,\textsuperscript{17} suggesting that the M1 mAChR-ERK signaling pathway in hippocampal neurons is likely to regulate memory \textit{in vivo}. Utilizing a muscarinic agonist carbachol (CCh) as a ligand for M1 mAChR, the function of M1 mAChR can be evaluated in a simple \textit{in vitro} system based on the M1 mAChR-ERK signaling pathway. In neuronal cell lines such as PC12 and F11 cells, CCh treatment induces rapid ERK phosphorylation through M1 mAChR.\textsuperscript{14,18}

Drugs for AD should be safe with few side effects because they will be used for an extended period of time. To obtain ingredients that promote M1 mAChR function, we performed a functional screening of natural products that have been used in humans for centuries and have been proven to be safe using the CCh-induced ERK phosphorylation system \textit{in vitro} (data not shown). Finally, we found that pretreatment of F11 cells with extracts from \textit{Cordyceps sinensis} (CS) significantly augments CCh-induced ERK phosphorylation.

CS is a fungus parasitic to \textit{Hepialidae} larvae and has been used as a traditional medicine in China. In many studies it has been shown that CS possesses various biological activities that support human homeostasis such as antitumor,\textsuperscript{19,20} antiooxidant,\textsuperscript{21,22} immunomodulatory,\textsuperscript{23–25} hypoglycemic,\textsuperscript{26,27} vasorelaxant activities,\textsuperscript{28} and antidepressant activity.\textsuperscript{29} A methanol extract from \textit{Cordyceps ophioglossoides}, a similar parasitic mushroom, was reported to scavenge the reactive oxygen species (ROS) generated by Aβ peptides.\textsuperscript{30} A hot water extract from CS was also reported to elicit antiaging effects, including improvement of memory function, from mice aged by D-galactose through upregulation of ROS scavenging activities.\textsuperscript{31} The effect of CS extracts on cholinergic neurotransmission, however, remains to be addressed.

In the present study, we evaluated the effect of CS extracts on M1 mAChR function \textit{in vitro} and also reported the \textit{in vivo} effect of CS extracts on an anti-cholinergic drug-induced memory impairment model.

**Material and methods**

**Materials**

A rabbit polyclonal antibody against phospho-extracellular signal-regulated kinase 1/2 (p-ERK1/2) (Thr\textsuperscript{202}/Tyr\textsuperscript{204}) was obtained from Cell Signaling Technology (Beverly, MA). A rabbit polyclonal antibody against total-ERK1/2 (t-ERK1/2) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Carbamylcholine chloride (carbachol, CCh) and scopolamine hydrobromide were obtained from Sigma-Aldrich (St. Louis, MO). Extracts from \textit{Cordyceps sinensis} (CS) were provided by Noevir Co. Ltd (Tokyo, Japan). Pirenzepine (PIR) and dicyclomine (DCM) were provided by Sigma-Aldrich. Other reagents described here are commercially available.

**Preparation of CS extracts**

A hot water extract of CS (HWCS) was prepared by boiling 10 g of CS in 200 g of water at approximately 100°C for 90 minutes, followed by filtration and freeze-drying (yield: approximately 30\%).\textsuperscript{29} An ethanol (EtOH) extract of CS (ECS) was obtained from residues of HWCS in 100 g of EtOH (>99.5%) at approximately 80°C for 60 minutes, followed by filtration and freeze-drying (yield: approximately 8\%). A mixed extract of HWCS and ECS (HW + E) was prepared by filtering and freeze-drying the mixture of each extract obtained from 10 g of CS. All extracts were dissolved in sterile deionized distilled water for treatments. Quality of the extracts was carefully controlled by using CS originating from a restricted area of Tibet. Preparation of the extracts was repeated at least three times and we observed essentially the same results for each of the extracts.

**Cell culture and treatments**

F11 neurohybrid cells were grown in Ham’s F12 medium containing 18% FBS as described previously.\textsuperscript{14,32} For ERK phosphorylation assays, F11 (at 1.2 × 10\textsuperscript{5} per well in a 6-well plate, cultured in serum-free media for 24 hours) were incubated with indicated doses of CS extracts for 30 minutes. Cells were washed twice with serum-free media and were then treated with 5 μM CCh for 5 minutes.\textsuperscript{14,34} Cells were harvested in a lysis buffer containing phosphatase inhibitors (50 mM Tris HCl [pH 7.4], 150 mM NaCl, 1% Triton-X 100, Complete protease inhibitors [Roche Applied
Cordyceps sinensis extracts improve cognitive function

Science; Mannheim, Germany], 1 mM EDTA, phosphatase inhibitor cocktails 1 and 2 [Sigma-Aldrich]). Samples (20 µg protein/lane) were subjected to normal SDS-PAGE and were then blotted onto PVDF membranes. The membranes were soaked with appropriate primary antibodies (p-ERK1/2, 1:1000; t-ERK1/2, 1:3000) and then with HRP-labeled secondary antibodies (BioRad Laboratories; Hercules, CA). Immunoreactive bands were detected using ECL Western Blotting Detection Reagents (Amersham Bioscience; Uppsala, Sweden). Densitometric analyses were performed using ImageJ 1.42q (http://rsb.info.nih.gov/ij/index.html).

Animals and treatments

This study was conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals of KEIO University School of Medicine. All experimental procedures were approved by the Institutional Animal Experiment Committee at KEIO University.

Male CD-1 mice aged 8 weeks were purchased from Charles River Japan Inc. (Kanagawa, Japan), kept at least for one week in a specific pathogen-free animal facility (23 ± 1°C, 50 ± 5% humidity), under a 12 hour light : dark cycle (07.00–19.00 hours). They were fed ad libitum with γ-ray-irradiated Picolab Rodent Diet 20 (PMI Feeds, St Louis, MO, USA) and sterilized deionized distilled water supplemented with sodium hypochlorite (5 ppm). Plastic cages (CLEA Japan, Tokyo, Japan) were autoclaved and ALPHA-dri bedding material (Shepherd Specialty Papers, Kalamazoo, MI, USA) was sterilized by heating at 80°C for 12 hours before use and changed once a week. Mice were handled by experienced researchers engaged in daily husbandry of the tested animals, in a quiet environment adjoining the room for housing. An open field test (OF) was performed as described previously to habituate the mice to the experimental conditions.31,32 A Y-maze test (YM) was performed as described.31,32 The apparatus for YM was made of gray plastic, with each arm 40 cm long, 12 cm high, 3 cm wide at the bottom, and 10 cm wide at the top. The three arms were connected at an angle of 120°. Mice were individually placed at the end of an arm and allowed to explore the maze freely for 8 minutes. Spontaneous alternation percentage (SA%), defined as a ratio of the arm choices that differed from the previous two choices (“successful choices”) to total choices during the run (“total entry minus two” because the first two entries could not be evaluated), was measured as an index of spatial working memory in YM. A passive avoidance test (PA) was performed as described.14,34 Briefly, mice were first confined in an illuminated chamber for 15 seconds and then allowed to enter an adjacent dark chamber. Soon after the mice entered the dark chamber, they were given an inescapable electric shock (0.3 mA, 3 seconds, once) through the floor grid. Each mouse was again tested in the apparatus 24 hours later. Entry latency was defined as time elapsed until the mouse entered into the dark chamber (maximum 300 seconds) was measured as an index of contextual memory in PA.

Statistical analyses

All values in the figures are shown as means ± SEM. Statistical analysis was performed with one-way analysis of variance (ANOVA) in which the alpha value was set at 0.05 and was assessed, followed by a Tukey’s post-hoc multiple comparison. All data were analyzed using Prism 5 (Ver.5.0b) software (GraphPad Software, Inc.; San Diego, CA).

Results

Effects of CS extracts on CCh-induced ERK phosphorylation through M1 mAChR in F11 neurohybrid cells

A muscarinic agonist CCh is reported to induce ERK phosphorylation in a dose-dependent fashion in neuronal cell lines such as PC12 pheochromocytoma cells and F11 neurohybrid cells.14,15 To test if ERK phosphorylation induced by CCh requires specific activation of M1 mAChR, we treated F11 cells with CCh together with pirenzepine (PIR) and dicyclomine (DCM), which are highly specific competitive antagonists for M1 mAChR (Figure 1A).14,15 CCh induced a robust increase in ERK phosphorylation. PIR and DCM almost completely inhibited ERK phosphorylation induced by CCh, suggesting that ERK phosphorylation by CCh in F11 cells is largely due to the stimulation of M1 mAChR.

To search for safe ingredients that promote M1 mAChR function, we pretreated F11 cells with a number of extracts from natural products and examined CCh-induced ERK phosphorylation by immunoblot analyses (data not shown). We finally found that extracts from CS significantly augment CCh-induced ERK phosphorylation. Considering that ingredients will differ according to the methods of extract preparation, we examined the effect of multiple types of CS extracts at 10 µg/mL on CCh-induced ERK phosphoryla-
tion in F11 cells (Figure 1B). Neither pretreatment with a hot water extract (HWCS) nor that with an ethanol extract from CS (ECS) affected ERK phosphorylation induced by CCh. In clear contrast, a mixed extract of HWCS and ECS (HW + E) significantly augmented ERK phosphorylation induced by CCh. None of the CS extracts affected total ERK protein levels. We further observed a CS extract dose-dependent increase in CCh-induced ERK phosphorylation (Figure 1C). A mixed extract (HW + E) of 100 µg/mL elicited the strongest effect on ERK phosphorylation.

To confirm the effect of a mixed extract (HW + E) on M1 mAChR, we repeated the experiments and performed densitometric analyses of the ratio of phosphorylated ERK to total ERK proteins (Figure 1D). Pretreatment with CS extracts (HW + E) at 100 µg/mL itself did not affect ERK phosphorylation, while pretreatment with CS extracts (HW + E) significantly augmented the rapid elevation of ERK phosphorylation levels induced by CCh treatment in F11 cells. CCh-induced ERK phosphorylation in F11 cells pretreated with CS extracts was approximately twice as high as that in F11 cells with vehicle pretreatment. The data indicated that a mixed extract upregulated ERK phosphorylation by CCh treatment by promoting M1 mAChR function.

Effects of PIR on CS extracts-induced increase in ERK phosphorylation by CCh treatment in F11 cells

Next, we tried to characterize the effect of CS extracts on M1 mAChR function. To this end, we treated F11 cells with CS extracts (HW + E) together with or without PIR, a specific M1 antagonist for 30 minutes and then treated with CCh in the absence of PIR (Figure 2A). As a result, we observed a significant increase in CCh-induced ERK phosphorylation by CS extracts, as in Figure 1, regardless of pretreatment with PIR, suggesting that the effect of CS extracts on ERK phosphorylation induced by CCh is not due to direct binding of CS extracts to M1 mAChR.

We also examined the effect of PIR treatment simultaneously with CCh treatment to confirm that the increased ERK phosphorylation by CS extracts is truly dependent on M1 mAChR. Without PIR treatment, we observed a significant increase in CCh-induced ERK phosphorylation by pretreatment with CS extracts (HW + E) (Figure 2B). In contrast to the pretreatment of CS extracts and PIR, PIR almost completely suppressed CCh-induced ERK phosphorylation in both cells with and without pretreatment with CS extracts, suggesting that the increased ERK phosphorylation in both cells with and without pretreatment with CS extracts, suggesting that the increased ERK phosphorylation in both cells with and without pretreatment with CS extracts, suggesting that the increased ERK phosphorylation in both cells.

Figure 1 Effects of CS extracts on CCh-induced ERK phosphorylation in F11 cells. A) Representative immunoblots of lysates (20 µg/lane) of cells treated with vehicle or 10 µM CCh together with M1 specific inhibitors, pirenzepine (PIR), and dicyclomine (DCM). F11 cells were treated with 10 µM CCh for 5 min together with dimso (0.5%), PIR (1 µM), or DCM (1 µM). Immunoblot analyses were performed with antibodies against phospho-ERK (p-ERK) and total-ERK (t-ERK) (both antibodies recognize ERK1 (42 kDa) and ERK2 (44 kDa)). Densitometrical ratios of p-ERK1 to t-ERK1 of the picture were indicated under the panel. B) Representative immunoblots of lysates (20 µg/lane) of cells treated with vehicle or 5 µM CCh together with pretreatments of multiple types of CS extracts. F11 cells were first treated for 30 min with a hot water extract (HWCS), an ethanol extract (ECS), a mixed extract of HWCS and ECS (HW-E) of CS dissolved in sterile deionized distilled water at 10 µg/mL. Then, the cells were treated with 5 µM CCh for 5 min. Immunoblot analyses were similarly performed with antibodies against p-ERK and t-ERK. Densitometrical ratios of p-ERK1 to t-ERK1 of the picture were indicated under the panel. C) Representative immunoblots of lysates (20 µg/lane) of cells similarly treated with vehicle (veh) or 5 µM CCh together with pretreatment of a mixed extract of HWCS and ECS (HW-E) at 100 µg/mL. Densitometrical ratios of p-ERK1 to t-ERK1 of the picture were indicated under the panel. D) Densitometry of three independent experiments or immunoblots of cells treated with or without a mixed CS extract (HW+E) at 100 µg/mL. The densitometry of the ratio of p-ERK to t-ERK was calculated using Image J software. The data are shown as means ± SEM. One-way ANOVA revealed a significant difference among the groups (F(5,20) = 137.6; P < 0.0001). **P < 0.01 by a Tukey’s post hoc test.
**Oral administration of CS extracts ameliorates memory impairment caused by scopolamine in CD-1 mice**

Administration of anti-cholinergic drugs such as scopolamine, 3-quinuclidinyl benzilate (3-QNB), and ethylcholine aziridium (AF64A) have been reported to induce memory impairment in both rodents and humans by disturbing the function of mACHR.36–38 We examined the effect of oral administration of CS extracts (HW + E) on scopolamine-induced amnesia model mice (Figure 3A). Subcutaneous injection of scopolamine significantly decreased spontaneous alternation percentage (SA%), an index of memory in YM, while oral administration of CS extracts (HW + E) significantly attenuated scopolamine-induced decrease in SA% (Figure 3B).

We subsequently performed a passive-avoidance task (PA) to evaluate the effect of CS extracts on contextual memory impairment. In the training session or memory acquisition session (Day 1), there were no differences in the entry latencies among the four treatment groups (Figure 3C, left). In the test session or memory retention trial (Day 2), the entry latencies of the mice receiving s.c. saline injection together with the oral vehicle (water) pretreatment or CS

---

**Figure 2** Effects of PiR on CS-induced increase in ERK phosphorylation by CCh in F11 cells. **A** Effects of the pretreatment with PiR (1 µM) on CS-induced increase in p-ERK by CCh. Representative immunoblots of lysates (20 µg/lane) of cells treated with vehicle or 5 µM CCh. F11 cells were first pretreated with vehicle or CS extracts (HW + E at 10 µg/ml) in the presence or absence of PiR (1 µM), and they were then treated with or without 10 µM CCh for 5 min. Densitometrical ratios of p-ERK1 to t-ERK1 of the picture were indicated under the panel. **B** Effects of PiR (1 µM) on CCh-induced p-ERK. Representative immunoblots of lysates (20 µg/lane) of cells treated with vehicle (veh) or 5 µM CCh together with or without PiR (1 µM). F11 cells were first treated for 30 min with each extract (HW + E) at 10 µg/ml. Cells were then treated with 5 µM CCh for 5 min together with dmso or PiR (1 µM). The densitometrical ratios of p-ERK1 to t-ERK1 of the picture were indicated under the panel.

**Figure 3** Behavioral analyses of scopolamine-induced amnesia model orally treated with CS extracts. **A** A schematic description of the experimental schedule. OF, an open field test; YM, a Y-maze test; PA, a passive avoidance test (PA1 represents a training session and PA2 represents a test session). OF, YM, and PA were sequentially performed. We examined the effect of orally (per os or per oral, p.o.)-administered CS extracts (HW + E, 100 mg/kg) on memory impairment induced by subcutaneously (s.c.)-injected scopolamine (1.0 mg/kg). The time point when a mouse tested in YM was defined as zero. OF, CS administration, and scopolamine injection were performed 24 hours, 6 hours, and 45 minutes before YM, respectively. PA1 was performed 3 hours after YM without additional injection of scopolamine. PA2 was performed 27 hours after YM (24 hours after PA1). **B** Results of spontaneous alternation% (SA%) in YM of mice treated with CS extracts together with scopolamine. Random choices in YM, which suggest loss of memory, will result in 50% (indicated as a broken line). Data are shown as means ± SEM. ANOVA revealed a significant difference (F(3,11) = 14.02; P < 0.0001). *P < 0.05 by a Tukey’s post hoc test. **C** Results of entry latencies in PA. Data are shown as means ± SEM. One-way ANOVA revealed a significant difference (F(3,6) = 3.822; P = 0.0258). ***P < 0.05 by a Tukey’s post hoc test.
extracts were robustly prolonged as compared with those in the training session, suggesting that the mice without scopolamine treatment acquired contextual memory in PA on Day1 and that the memory was retained at least for 24 hours (Figure 3C, right). The entry latency of the mice receiving s.c. scopolamine injection together with the oral vehicle pretreatment in the test session was equivalent to that in the training session, suggesting that scopolamine treatment almost completely inhibited memory acquisition in the training session. Oral pretreatment with CS extract, in clear contrast, significantly prolonged the entry latency of the mice with scopolamine injection, suggesting that CS extracts attenuated scopolamine-induced memory impairment (Figure 3C, right). Thus, CS extract is likely to prevent memory impairment related to the dysfunction of mAChR.

Discussion

In the present study we aimed to identify natural ingredients promoting M1 mAChR by using an in vitro functional assay system based on ERK phosphorylation induced by CCh. The ERK phosphorylation caused by CCh in F11 cells is deemed to be dependent on M1 mAChR function because the specific M1 mAChR inhibitor completely abolishes, and ectopic overexpression of M1 mAChR augmented, the ERK phosphorylation by CCh.14 Using the in vitro system, we have first found that CS extracts is likely to promote M1 mAChR function in vitro. Using an antimuscarinic drug scopolamine-induced memory impairment model, we further confirmed that CS extracts improve M1 mAChR in vivo as well. This is the first study in which the effects of CS extracts on M1 mAChR are reported.

CS has long been used as a traditional Chinese medicine to ameliorate conditions associated with aging and senescence, such as weakness in the loins and knees, or fatigue. Multiple researches have shown that CS contains crude protein, D-mannitol, cordycepin,39,40 and cordyceps polysaccharide41 as bioactive constituents. Considering that memory dysfunction is a common symptom of aging,15,42,43 polysaccharide41 as bioactive constituents. Considering that a mixed extract (HW + E) contains such active components. CS extracts may serve as a potential therapy which could be used to treat memory dysfunction related to AD.

Acknowledgment/disclosure

The authors are grateful to the late Prof Ikuo Nishimoto and also thank Ms T Hiraki and T Yoshida-Nishimoto for indispensable support, and Messrs S Hayashi, A Goto, and K Yamashita for animal husbandry. This work was supported in part by grants from the Fumi Yamamura Memorial Foundation for Female Natural scientists (MY is a Yamamura Fellow), the KEIO Gijuku Academic Development Funds (TC), and Noevir Co. Ltd. KT and MI are employees of Noevir Co. Ltd. Study funders include Noevir Co. Ltd., however, these companies had no role in study design, data collection, or analysis. Author contributions are as follows: TC and MY conceived of and designed the experiments; KT and MI prepared the CS extracts; MY, MS, and JS performed the experiments; TC analyzed the data; TC, MS, JS, and SA wrote the paper.

References


